Proteomic Quantification of Lysine Acetylation and Succinylation Profile Alterations in Lung Adenocarcinomas of Non-Smoking Females

• Published in: YONAGO ACTA MEDICA 2022, Vol.65 (2), p.132-147
• Main Authors: Wu, Jun, Li, Ning, Huang, Xiaoqin, Chen, Jianming, Jia, Yufang, He, Zhan, Mo, Ting, He, Liuyan, Wang, Yajun, Zhang, Haitao
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 0513-5710; 1346-8049
• DOI: 10.33160/yam.2022.05.006

[ABSTRACT] [Background] Epidemiological surveys in recent years have shown that the incidence of female lung adenocarcinomas has multiplied in both smoking and non-smoking populations. The cause of lung adenocarcinomas is still not clear. Protein post-translational modification is one of the causes of the development of cancer cells. [Methods] Lung adenocarcinoma and paracancerous tissue samples were collected from female patients with no history of smoking. The differences in protein acetylation and succinylation of cancerous tissues and paracancerous tissues were analysed by LC-MS/MS with a TMT labelling method. We distinguished the differentially modified proteins and annotated these proteins in terms of Go annotation, protein domains, protein complex analysis and KEGG pathway analysis. [Results] 972 acetylation sites on 556 proteins were identified, among which 875 Kac sites on 507 proteins were quantified, 2373 succinylation sites on 1205 proteins were identified, and 2205 Ksu sites on 1131 proteins were quantified. The acetylation levels of proteins, which contribute to DNA binding and gene expression regulation, were up-regulated. The proteins for which the succinylation levels were up-regulated were mainly involved in mitochondria carboxylic acid metabolism. We also identified simultaneously up-regulated or down-regulated acetylated and succinylated proteins and depicted their interaction network. [Conclusion] This study provides insight into lung adenocarcinomas acetylation and succinylation profile alterations in carcinoma pathogenesis and provides a potential therapeutic target for lung adenocarcinomas.